Otsuka Europe website: outdated partner statement ruled inaccurate (AUTH/3748/2/23)

📅 2023 | 🖉 Dr Anzal Qurbain
📊

Key facts

Case numberAUTH/3748/2/23
CompanyOtsuka Pharmaceuticals Europe Ltd
MaterialOtsuka Europe website webpage headed “Therapy Areas in Europe”
Main issueOut-of-date/inaccurate statement about working with “partners Akebia and Aurinia” exploring treatment options for CKD anaemia and Lupus Nephritis
Applicable Code2021
BreachClause 6.1
ComplainantAnonymous, non-contactable complainant (ex-employee)
Complaint received28 February 2023
Case completed4 June 2024
AppealNo appeal
SanctionsUndertaking received; additional sanctions not stated

Download the full case report (PDF)


Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI
🎬 Expert Video Walkthrough
🎬
Video walkthrough — coming for members
Subscribe now and get expert video analysis for every case as we publish them.
Subscribe — from £299/yr
📋

What happened

  • An anonymous, non-contactable complainant (described as an ex-employee) complained about an Otsuka Europe website page titled “Therapy Areas in Europe”.
  • The Nephrology section stated Otsuka was working with patients/HCPs on kidney disease awareness and, “together with our partners Akebia and Aurinia, are exploring treatment options for patients with anaemia related to chronic kidney disease and Lupus Nephritis.”
  • The complainant alleged the statement was updated in December 2021 but became out of date/false after Otsuka and Akebia cancelled their agreement (June 2022).
  • Otsuka explained it had terminated co-development/licence arrangements with Akebia (notification in May 2022; termination and settlement agreement in June 2022) and accepted the website statement was now inaccurate/obsolete.
  • Otsuka amended the webpage to remove reference to Akebia and anaemia related to chronic kidney disease.
⚖️

Outcome

  • Breach of Clause 6.1 (Providing inaccurate information).
  • No appeal.
🔒

Unlock the full case analysis

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value
£249/year
Annual — save £99
or
£29/mo
Monthly
Join Now — Instant Access

⭐ Business Intelligence Access

See the full compliance picture for every pharma company

291 Company Intelligence Reports — breach patterns, appeal history, industry ranking, PDF export.

Request Access →
⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week — free.

Subscribe Free
🎓 AQP Training